Summary: The fiscal year 2026 (FY26) Peer Reviewed Cancer Research Program (PRCRP) Clinical Trial Award (CTA) supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of cancer within at least one of the FY26 PRCRP Topic Areas. Clinical trials proposed may evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept trials (e.g., pilot, first-in-human, phase 0) that evaluate the effects of interventions or inform the design of more advanced trials to large-scale trials (up to phase III) to determine efficacy in relevant patient populations.
Distinctive Features:
• Applications to this award mechanism must include a clinical trial.
• Projects can range from phase 0 to phase III.
• If an Investigational New Drug (IND) application, Investigational Device Exemption (IDE), or equivalent, is required, a regulatory application must be submitted to the relevant regulatory agency by the Clinical Trial Award application submission deadline. The regulatory application should be specific to the product and indication to be tested in the proposed clinical trial.
• Applications are required to include patient advocates.
• Animal studies are NOT allowed under this award mechanism. All preclinical work must be completed prior to the award start date.